Christian GAIDDON

DR2 CNRS – Responsable équipe 2

Profil Linkedin

(+33) 06 83 52 53 56

 

 

 

Liste des publications :

 

Beck, M., Baranger, M., Moufok-Sadoun, A., Bersuder, E., Hinkel, I., Mellitzer, G., Martin, E., Marisa, L., Duluc, I., de Reynies, A., Gaiddon, C., Freund, J.-N., & Gross, I. (2021). The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms. Oncogene, 40(3), 522–535. https://doi.org/10.1038/s41388-020-01546-y
Voisinet, M., Venkatasamy, A., Alratrout, H., Delhorme, J.-B., Brigand, C., Rohr, S., Gaiddon, C., & Romain, B. (2020). How to Prevent Sarcopenia Occurrence during Neoadjuvant Chemotherapy for Oesogastric Adenocarcinoma? Nutrition and Cancer, 1–7. https://doi.org/10.1080/01635581.2020.1770813
Solís-Ruiz, J. A., Barthe, A., Riegel, G., Saavedra-Díaz, R. O., Gaiddon, C., & Le Lagadec, R. (2020). Light activation of cyclometalated ruthenium complexes drives towards caspase 3 dependent apoptosis in gastric cancer cells. Journal of Inorganic Biochemistry, 208, 111080. https://doi.org/10.1016/j.jinorgbio.2020.111080
Licona, C., Delhorme, J.-B., Riegel, G., Vidimar, V., Cerón-Camacho, R., Boff, B., Venkatasamy, A., Tomasetto, C., da Silva Figueiredo Celestino Gomes, P., Rognan, D., Freund, J.-N., Le Lagadec, R., Pfeffer, M., Gross, I., Mellitzer, G., & Gaiddon, C. (2020). Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms. Inorganic Chemistry Frontiers, 7(3), 678–688. https://doi.org/10.1039/C9QI01148J
Miller, J. J., Blanchet, A., Orvain, C., Nouchikian, L., Reviriot, Y., Clarke, R. M., Martelino, D., Wilson, D., Gaiddon, C., & Storr, T. (2019). Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chemical Science, 10(46), 10802–10814. https://doi.org/10.1039/c9sc04151f
Spaety, M.-E., Gries, A., Badie, A., Venkatasamy, A., Romain, B., Orvain, C., Yanagihara, K., Okamoto, K., Jung, A. C., Mellitzer, G., Pfeffer, S., & Gaiddon, C. (2019). HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers, 11(11), 1747. https://doi.org/10.3390/cancers11111747
Coliat, P., Ramolu, L., Jégu, J., Gaiddon, C., Jung, A. C., & Pencreach, E. (2019). Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC. Cancers, 11(10). https://doi.org/10.3390/cancers11101607
Liang, Y., Hou, L., Li, L., Li, L., Zhu, L., Wang, Y., Huang, X., Hou, Y., Zhu, D., Zou, H., Gu, Y., Weng, X., Wang, Y., Li, Y., Wu, T., Yao, M., Gross, I., Gaiddon, C., Luo, M., … Meng, X. (2019). Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene. https://doi.org/10.1038/s41388-019-1035-8
Job, S., Reyniès, A. de, Heller, B., Weiss, A., Guérin, E., Macabre, C., Ledrappier, S., Bour, C., Wasylyk, C., Etienne-Selloum, N., Brino, L., Gaiddon, C., Wasylyk, B., & Jung, A. C. (2019). Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. Cancers, 11(6). https://doi.org/10.3390/cancers11060795
Santoro, A., Vileno, B., Palacios, Ò., Peris-Díaz, M. D., Riegel, G., Gaiddon, C., Krężel, A., & Faller, P. (2019). Reactivity of Cu(ii)-, Zn(ii)- and Fe(ii)-thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation. Metallomics: Integrated Biometal Science, 11(5), 994–1004. https://doi.org/10.1039/c9mt00061e
Vidimar, V., Licona, C., Cerón-Camacho, R., Guerin, E., Coliat, P., Venkatasamy, A., Ali, M., Guenot, D., Le Lagadec, R., Jung, A. C., Freund, J.-N., Pfeffer, M., Mellitzer, G., Sava, G., & Gaiddon, C. (2019). A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. Cancer Letters, 440–441, 145–155. https://doi.org/10.1016/j.canlet.2018.09.029
Miller, J. J., Orvain, C., Jozi, S., Clarke, R. M., Smith, J. R., Blanchet, A., Gaiddon, C., Warren, J. J., & Storr, T. (2018). Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer. Chemistry (Weinheim an Der Bergstrasse, Germany), 24(67), 17734–17742. https://doi.org/10.1002/chem.201802677
Lam, N. Y. S., Truong, D., Burmeister, H., Babak, M. V., Holtkamp, H. U., Movassaghi, S., Ayine-Tora, D. M., Zafar, A., Kubanik, M., Oehninger, L., Söhnel, T., Reynisson, J., Jamieson, S. M. F., Gaiddon, C., Ott, I., & Hartinger, C. G. (2018). From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. Inorganic Chemistry, 57(22), 14427–14434. https://doi.org/10.1021/acs.inorgchem.8b02634
Minault, Q., Gaiddon, C., Veillon, F., & Venkatasamy, A. (2018). The Champagne sign. Abdominal Radiology (New York), 43(10), 2888–2889. https://doi.org/10.1007/s00261-018-1544-x
Chow, M. J., Babak, M. V., Tan, K. W., Cheong, M. C., Pastorin, G., Gaiddon, C., & Ang, W. H. (2018). Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes. Molecular Pharmaceutics, 15(8), 3020–3031. https://doi.org/10.1021/acs.molpharmaceut.8b00003
Gass, B., Marrer, E., Bara, S., Ligier, K., Molinié, F., Colonna, M., Daubisse-Marliac, L., Trétarre, B., Lapôtre-Ledoux, B., Woronoff, A.-S., Guizard, A.-V., Bouvier, V., Troussard, X., Gaiddon, C., Klein, D., Velten, M., & Jégu, J. (2018). Use of a case-mix approach to study the trends in the incidence of second primary cancers. Annals of Epidemiology, 28(5), 322–327. https://doi.org/10.1016/j.annepidem.2018.02.008
Babak, M. V., Pfaffeneder-Kmen, M., Meier-Menches, S. M., Legina, M. S., Theiner, S., Licona, C., Orvain, C., Hejl, M., Hanif, M., Jakupec, M. A., Keppler, B. K., Gaiddon, C., & Hartinger, C. G. (2018). Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. Inorganic Chemistry, 57(5), 2851–2864. https://doi.org/10.1021/acs.inorgchem.7b03210
Makarchuk, S., Beyer, N., Gaiddon, C., Grange, W., & Hébraud, P. (2018). Holographic Traction Force Microscopy. Scientific Reports, 8(1), 3038. https://doi.org/10.1038/s41598-018-21206-2
Manfredelli, S., Delhorme, J.-B., Venkatasamy, A., Gaiddon, C., Brigand, C., Rohr, S., & Romain, B. (2017). Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma? Annals of Surgical Oncology, 24(11), 3324–3330. https://doi.org/10.1245/s10434-017-5945-9
Chow, M. J., Alfiean, M., Pastorin, G., Gaiddon, C., & Ang, W. H. (2017). Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies. Chemical Science, 8(5), 3641–3649. https://doi.org/10.1039/c7sc00497d
Estrada‐Montaño, A. S., Ryabov, A. D., Gries, A., Gaiddon, C., & Lagadec, R. L. (2017). Iron(III) Pincer Complexes as a Strategy for Anticancer Studies. European Journal of Inorganic Chemistry, 2017(12), 1673–1678. https://doi.org/10.1002/ejic.201601350
Licona, C., Spaety, M.-E., Capuozzo, A., Ali, M., Santamaria, R., Armant, O., Delalande, F., Van Dorsselaer, A., Cianferani, S., Spencer, J., Pfeffer, M., Mellitzer, G., & Gaiddon, C. (2017). A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. Oncotarget, 8(2), 2568–2584. https://doi.org/10.18632/oncotarget.13711
Platet, N., Hinkel, I., Richert, L., Murdamoothoo, D., Moufok-Sadoun, A., Vanier, M., Lavalle, P., Gaiddon, C., Vautier, D., Freund, J.-N., & Gross, I. (2017). The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton. Cancer Letters, 386, 57–64. https://doi.org/10.1016/j.canlet.2016.10.040
Khalil, G., Orvain, C., Fang, L., Barloy, L., Chaumont, A., Gaiddon, C., Henry, M., Kyritsakas, N., & Mobian, P. (2016). Monomeric Ti(iv)-based complexes incorporating luminescent nitrogen ligands: synthesis, structural characterization, emission spectroscopy and cytotoxic activities. Dalton Transactions (Cambridge, England: 2003), 45(47), 19072–19085. https://doi.org/10.1039/c6dt03477b
Chow, M. J., Babak, M. V., Wong, D. Y. Q., Pastorin, G., Gaiddon, C., & Ang, W. H. (2016). Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes. Molecular Pharmaceutics, 13(7), 2543–2554. https://doi.org/10.1021/acs.molpharmaceut.6b00348
Chow, M. J., Licona, C., Pastorin, G., Mellitzer, G., Ang, W. H., & Gaiddon, C. (2016). Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance. Chemical Science, 7(7), 4117–4124. https://doi.org/10.1039/c6sc00268d
von Grabowiecki, Y., Abreu, P., Blanchard, O., Palamiuc, L., Benosman, S., Mériaux, S., Devignot, V., Gross, I., Mellitzer, G., Gonzalez de Aguilar, J. L., & Gaiddon, C. (2016). Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63. ELife, 5, e10528. https://doi.org/10.7554/eLife.10528
Rico Bautista, H., Saavedra Díaz, R. O., Shen, L. Q., Orvain, C., Gaiddon, C., Le Lagadec, R., & Ryabov, A. D. (2016). Impact of cyclometalated ruthenium(II) complexes on lactate dehydrogenase activity and cytotoxicity in gastric and colon cancer cells. Journal of Inorganic Biochemistry, 163, 28–38. https://doi.org/10.1016/j.jinorgbio.2016.07.014
Tasan, S., Licona, C., Doulain, P.-E., Michelin, C., Gros, C. P., Le Gendre, P., Harvey, P. D., Paul, C., Gaiddon, C., & Bodio, E. (2015). Gold-phosphine-porphyrin as potential metal-based theranostics. Journal of Biological Inorganic Chemistry: JBIC: A Publication of the Society of Biological Inorganic Chemistry, 20(1), 143–154. https://doi.org/10.1007/s00775-014-1220-8
von Grabowiecki, Y., Licona, C., Palamiuc, L., Abreu, P., Vidimar, V., Coowar, D., Mellitzer, G., & Gaiddon, C. (2015). Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy. The Journal of Pharmacology and Experimental Therapeutics, 352(1), 23–32. https://doi.org/10.1124/jpet.114.216879
Chow, M. J., Licona, C., Yuan Qiang Wong, D., Pastorin, G., Gaiddon, C., & Ang, W. H. (2014). Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly. Journal of Medicinal Chemistry, 57(14), 6043–6059. https://doi.org/10.1021/jm500455p
Klajner, M., Licona, C., Fetzer, L., Hebraud, P., Mellitzer, G., Pfeffer, M., Harlepp, S., & Gaiddon, C. (2014). Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. Inorganic Chemistry, 53(10), 5150–5158. https://doi.org/10.1021/ic500250e
Boff, B., Gaiddon, C., & Pfeffer, M. (2013). Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes. Inorganic Chemistry, 52(5), 2705–2715. https://doi.org/10.1021/ic302779q
Vidimar, V., Meng, X., Klajner, M., Licona, C., Fetzer, L., Harlepp, S., Hébraud, P., Sidhoum, M., Sirlin, C., Loeffler, J.-P., Mellitzer, G., Sava, G., Pfeffer, M., & Gaiddon, C. (2012). Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochemical Pharmacology, 84(11), 1428–1436. https://doi.org/10.1016/j.bcp.2012.08.022
Ribeiro, N., Thuaud, F., Bernard, Y., Gaiddon, C., Cresteil, T., Hild, A., Hirsch, E. C., Michel, P. P., Nebigil, C. G., & Désaubry, L. (2012). Flavaglines as potent anticancer and cytoprotective agents. Journal of Medicinal Chemistry, 55(22), 10064–10073. https://doi.org/10.1021/jm301201z
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012). Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry, 106(1), 90–99. https://doi.org/10.1016/j.jinorgbio.2011.09.030
Benosman, S., Meng, X., Von Grabowiecki, Y., Palamiuc, L., Hritcu, L., Gross, I., Mellitzer, G., Taya, Y., Loeffler, J.-P., & Gaiddon, C. (2011). Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. The Journal of Biological Chemistry, 286(50), 43013–43025. https://doi.org/10.1074/jbc.M111.261271
Fetzer, L., Boff, B., Ali, M., Xiangjun, M., Collin, J.-P., Sirlin, C., Gaiddon, C., & Pfeffer, M. (2011). Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier. Dalton Transactions (Cambridge, England: 2003), 40(35), 8869–8878. https://doi.org/10.1039/c1dt10322a
Thuaud, F., Ribeiro, N., Gaiddon, C., Cresteil, T., & Désaubry, L. (2011). Novel flavaglines displaying improved cytotoxicity. Journal of Medicinal Chemistry, 54(1), 411–415. https://doi.org/10.1021/jm101318b
Klajner, M., Hebraud, P., Sirlin, C., Gaiddon, C., & Harlepp, S. (2010). DNA binding to an anticancer organo-ruthenium complex. The Journal of Physical Chemistry. B, 114(44), 14041–14047. https://doi.org/10.1021/jp1044783
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., Bischoff, P., Sirlin, C., Pfeffer, M., Loeffler, J.-P., & Gaiddon, C. (2009). A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP. Cancer Research, 69(13), 5458–5466. https://doi.org/10.1158/0008-5472.CAN-08-4408
Ohtsubo, C., Shiokawa, D., Kodama, M., Gaiddon, C., Nakagama, H., Jochemsen, A. G., Taya, Y., & Okamoto, K. (2009). Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2. Cancer Science, 100(7), 1291–1299. https://doi.org/10.1111/j.1349-7006.2009.01180.x
Benosman, S., Gross, I., Clarke, N., Jochemsen, A. G., Okamoto, K., Loeffler, J.-P., & Gaiddon, C. (2007). Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis. Cell Death and Differentiation, 14(12), 2047–2057. https://doi.org/10.1038/sj.cdd.4402216
Gross, I., Armant, O., Benosman, S., de Aguilar, J. L. G., Freund, J.-N., Kedinger, M., Licht, J. D., Gaiddon, C., & Loeffler, J.-P. (2007). Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 14(10), 1802–1812. https://doi.org/10.1038/sj.cdd.4402188
Lokshin, M., Li, Y., Gaiddon, C., & Prives, C. (2007). p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Research, 35(1), 340–352. https://doi.org/10.1093/nar/gkl1047
Gross, I., Lhermitte, B., Domon-Dell, C., Duluc, I., Martin, E., Gaiddon, C., Kedinger, M., & Freund, J.-N. (2005). Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation. Oncogene, 24(54), 7955–7963. https://doi.org/10.1038/sj.onc.1208945
Gaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. P. (2005). Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. The Journal of Pharmacology and Experimental Therapeutics, 315(3), 1403–1411. https://doi.org/10.1124/jpet.105.089342
Di Scala, F., Dupuis, L., Gaiddon, C., De Tapia, M., Jokic, N., Gonzalez de Aguilar, J.-L., Raul, J.-S., Ludes, B., & Loeffler, J.-P. (2005). Tissue specificity and regulation of the N-terminal diversity of reticulon 3. The Biochemical Journal, 385(Pt 1), 125–134. https://doi.org/10.1042/BJ20040458
Gaiddon, C., Lokshin, M., Gross, I., Levasseur, D., Taya, Y., Loeffler, J.-P., & Prives, C. (2003). Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. The Journal of Biological Chemistry, 278(30), 27421–27431. https://doi.org/10.1074/jbc.M300251200